ArticleAsian journal of andrology

PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study.

Xin-Xing Du et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.